TRACON Pharmaceuticals Inc (TCON)

NASDAQ
4.270
-0.070(-1.61%)
After Hours
4.270
0.000(0.00%)
- Real-time Data
  • Volume:
    220,876
  • Bid/Ask:
    4.220/4.430
  • Day's Range:
    4.110 - 4.450

TCON Overview

Prev. Close
4.34
Day's Range
4.11-4.45
Revenue
350K
Open
4.34
52 wk Range
3.21-12.2
EPS
-1.6
Volume
220,876
Market Cap
82.97M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
288,036
P/E Ratio
-
Beta
1.84
1-Year Change
-11.23%
Shares Outstanding
19,430,369
Next Earnings Date
Nov 09, 2021
What is your sentiment on TRACON Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.

TRACON Pharmaceuticals Inc News

TRACON Pharmaceuticals Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyNeutralBuyBuyStrong Sell
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Sell
SummaryNeutralSellStrong BuyStrong BuyStrong Sell

TRACON Pharmaceuticals Inc Company Profile

TRACON Pharmaceuticals Inc Company Profile

Employees
18

TRACON Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of targeted therapeutics for cancer. The Company's product pipelines consist of Envafolimab (KN035), Methoxyamine (TRC102), TJ004309 and Bispecific Antibodies. KN035 is a single-domain PD-L1 antibody that is administered by subcutaneous injection without the need for an adjuvant. KN035 is in Phase II of clinical trials. TRC102 is a clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is in multiple Phase I and Phase II clinical trials. TJ004309 is a humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which is an immunosuppressive metabolite adenosine.

Read More
  • Any news
    0
    • strong?
      0
      • thaxs
        0
        • Trc105 postive results released today for liver cancer.
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.